NAFLD and liver transplantation: Disease burden, current management and future challenges

Kim, 2008, Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome, Cleve Clin J Med, 75, 721, 10.3949/ccjm.75.10.721 Eslam, 2020, A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement, J Hepatol, 73, 202, 10.1016/j.jhep.2020.03.039 Kuchay, 2020, From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): a journey over 40 years, Diabetes Metab Syndr, 14, 695, 10.1016/j.dsx.2020.05.019 Fouad, 2020, What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’, Liver Int, 40, 1254, 10.1111/liv.14478 Lin, 2020, Comparison of MAFLD and NAFLD diagnostic criteria in real world, Liver Int, 40, 2082, 10.1111/liv.14548 Bedossa, 2017, Pathology of non-alcoholic fatty liver disease, Liver Int, 37, 85, 10.1111/liv.13301 Younossi, 2019, Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol, 17, 748, 10.1016/j.cgh.2018.05.057 Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021 Ong, 2005, Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients, Obes Surg, 15, 310, 10.1381/0960892053576820 Cotter, 2020, Nonalcoholic steatohepatitis after liver transplantation, Liver Transpl, 26, 141, 10.1002/lt.25657 Adam, 2018, 2018 Annual report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation, Transpl Int, 31, 1293, 10.1111/tri.13358 Estes, 2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466 Anstee, 2019, From NASH to HCC: current concepts and future challenges, Nat Rev Gastroenterol Hepatol, 16, 411, 10.1038/s41575-019-0145-7 Calzadilla Bertot, 2016, The natural course of non-alcoholic fatty liver disease, Int J Mol Sci, 17, 774, 10.3390/ijms17050774 Kolly, 2016, Surveillance for hepatocellular carcinoma in patients with NASH, Diagnostics (Basel), 6, 22, 10.3390/diagnostics6020022 Haldar, 2019, Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study, J Hepatol, 71, 313, 10.1016/j.jhep.2019.04.011 Young, 2016, Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma, Liver Transpl, 22, 1356, 10.1002/lt.24507 Thuluvath, 2019, Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis, Transplantation, 103, 113, 10.1097/TP.0000000000002355 van den Berg, 2018, Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity, Dig Liver Dis, 50, 68, 10.1016/j.dld.2017.08.022 Adam, 2003, Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry, Liver Transpl, 9, 1231, 10.1016/j.lts.2003.09.018 Charlton, 2011, Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States, Gastroenterology, 141, 1249, 10.1053/j.gastro.2011.06.061 Nagai, 2019, Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies, Clin Gastroenterol Hepatol, 17, 2759, 10.1016/j.cgh.2019.04.033 Saeed, 2019, Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis, Transplantation, 103, e345, 10.1097/TP.0000000000002916 Narayanan, 2019, Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation, Transplantation, 103, e14, 10.1097/TP.0000000000002317 Gitto, 2018, De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients, Eur J Gastroenterol Hepatol, 30, 766, 10.1097/MEG.0000000000001105 Thuluvath, 2019, Poor survival after retransplantation in NASH cirrhosis, Transplantation, 103, 101, 10.1097/TP.0000000000002135 Pfeiffenberger, 2019, Routine liver elastography could predict actuarial survival after liver transplantation, J Gastrointestin Liver Dis, 28, 271, 10.15403/jgld-218 Singh, 2016, Diagnostic accuracy of magnetic resonance elastography in liver transplant recipients: a pooled analysis, Ann Hepatol, 15, 363, 10.5604/16652681.1198808 Sadler, 2018, Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma, Transplantation, 102, 640, 10.1097/TP.0000000000002043 Leite, 2009, Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus, Liver Int, 29, 113, 10.1111/j.1478-3231.2008.01718.x John, 2002, Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus, Liver Transpl, 8, 708, 10.1053/jlts.2002.34638 Younossi, 2014, The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US, Aliment Pharmacol Ther, 40, 686, 10.1111/apt.12881 Orsi, 2017, Hepatogenous diabetes: is it time to separate it from type 2 diabetes?, Liver Int, 37, 950, 10.1111/liv.13337 Grancini, 2019, Central role of the beta-cell in driving regression of diabetes after liver transplantation in cirrhotic patients, J Hepatol, 70, 954, 10.1016/j.jhep.2019.01.015 Grancini, 2019, Management of diabetes mellitus in patients undergoing liver transplantation, Pharmacol Res, 141, 556, 10.1016/j.phrs.2019.01.042 Gangopadhyay, 2017, Consensus statement on dose modifications of antidiabetic agents in patients with hepatic impairment, Indian J Endocrinol Metab, 21, 341, 10.4103/ijem.IJEM_512_16 Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367 Watt, 2011, Metabolic syndrome: is immunosuppression to blame?, Liver Transpl, 17, S38, 10.1002/lt.22386 Ramos-Prol, 2017, Outcomes in patients with diabetes 10 years after liver transplantation, J Diabetes, 9, 1033 Bhat, 2018, New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant: a machine learning approach, Mayo Clin Proc, 93, 1794, 10.1016/j.mayocp.2018.06.020 Davidson, 2004, International expert panel on new-onset diabetes after T. New-onset diabetes after transplantation 2003 international consensus guidelines: an endocrinologist's view, Diabetes Care, 27, 805, 10.2337/diacare.27.3.805 Saab, 2006, Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation, Am J Transplant, 6, 1890, 10.1111/j.1600-6143.2006.01385.x Delgado-Borrego, 2004, Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation, Transplantation, 77, 703, 10.1097/01.TP.0000114283.04840.3A Luther, 2004, Pioglitazone in the management of diabetes mellitus after transplantation, Am J Transplant, 4, 2135, 10.1111/j.1600-6143.2004.00613.x Villanueva, 2005, Rosiglitazone therapy of posttransplant diabetes mellitus, Transplantation, 80, 1402, 10.1097/01.tp.0000181165.19788.95 Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774 Bae, 2016, Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study, Endocrinol Metab (Seoul), 31, 161, 10.3803/EnM.2016.31.1.161 Sanyal, 2013, A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting, Indian J Endocrinol Metab, 17, S203, 10.4103/2230-8210.119572 Kuchay, 2018, Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial), Diabetes Care, 41, 1801, 10.2337/dc18-0165 Sasaki, 2014, Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments, Front Endocrinol (Lausanne), 5, 164, 10.3389/fendo.2014.00164 Czigany, 2020, Myosteatosis to predict inferior perioperative outcome in patients undergoing orthotopic liver transplantation, Am J Transplant, 20, 493, 10.1111/ajt.15577 Berzigotti, 2011, Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis, Hepatology, 54, 555, 10.1002/hep.24418 Sundaram, 2015, Obesity is independently associated with infection in hospitalised patients with end-stage liver disease, Aliment Pharmacol Ther, 42, 1271, 10.1111/apt.13426 LaMattina, 2012, Complications associated with liver transplantation in the obese recipient, Clin Transplant, 26, 910, 10.1111/j.1399-0012.2012.01669.x Nuffer, 2015, Liraglutide: a new option for the treatment of obesity, Pharmacotherapy, 35, 926, 10.1002/phar.1639 Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X Assy, 2007, Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis, Gut, 56, 443, 10.1136/gut.2006.106021 Leblanc, 2011, Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force, Ann Intern Med, 155, 434, 10.7326/0003-4819-155-7-201110040-00006 Polyzos, 2019, Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics, Metabolism, 92, 82, 10.1016/j.metabol.2018.11.014 Weiner, 2010, Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, Dig Dis, 28, 274, 10.1159/000282102 Furuya, 2007, Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years, J Gastroenterol Hepatol, 22, 510, 10.1111/j.1440-1746.2007.04833.x Reverter, 2019, The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery, J Hepatol, 71, 942, 10.1016/j.jhep.2019.07.007 Zamora-Valdes, 2018, Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy, Hepatology, 68, 485, 10.1002/hep.29848 Richards, 2005, Weight gain and obesity after liver transplantation, Transpl Int, 18, 461, 10.1111/j.1432-2277.2004.00067.x Everhart, 1998, Weight change and obesity after liver transplantation: incidence and risk factors, Liver Transpl Surg, 4, 285, 10.1002/lt.500040402 Neuberger, 2019, Sport and exercise in improving outcomes after solid organ transplantation: overview from a UK meeting, Transplantation, 103, S1, 10.1097/TP.0000000000002710 Totti, 2019, Physical condition, glycemia, liver function, and quality of life in liver transplant recipients after a 12-month supervised exercise program, Transplant Proc, 51, 2952, 10.1016/j.transproceed.2019.03.087 Cassiman, 2006, Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial, Transpl Int, 19, 1000, 10.1111/j.1432-2277.2006.00379.x Diwan, 2018, Liver transplantation and bariatric surgery: timing and outcomes, Liver Transpl, 24, 1280, 10.1002/lt.25303 Salomone, 2020, Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: evidence and perspectives, Liver Int, 40, 1262, 10.1111/liv.14441 Gojowy, 2016, High frequency of arterial hypertension in patients after liver transplantation, Transplant Proc, 48, 1721, 10.1016/j.transproceed.2015.11.043 Issa, 2015, Long-term management of liver transplant recipients: a review for the internist, Cleve Clin J Med, 82, 361, 10.3949/ccjm.82a.14072 Guckelberger, 2009, Long-term medical comorbidities and their management: hypertension/cardiovascular disease, Liver Transpl, 15, S75, 10.1002/lt.21903 Galioto, 2008, Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial, Liver Transpl, 14, 1020, 10.1002/lt.21442 Fussner, 2015, Cardiovascular disease after liver transplantation: when, what, and who is at risk, Liver Transpl, 21, 889, 10.1002/lt.24137 Sheiner, 2000, Long-term medical complications in patients surviving > or = 5 years after liver transplant, Transplantation, 69, 781, 10.1097/00007890-200003150-00018 Ling, 2012, Major influence of renal function on hyperlipidemia after living donor liver transplantation, World J Gastroenterol, 18, 7033, 10.3748/wjg.v18.i47.7033 Mach, 2020, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J, 41, 111, 10.1093/eurheartj/ehz455 Watt, 2010, Metabolic syndrome and liver transplantation: a review and guide to management, J Hepatol, 53, 199, 10.1016/j.jhep.2010.01.040 Page, 2005, Drug therapy in the heart transplant recipient: part IV: drug-drug interactions, Circulation, 111, 230, 10.1161/01.CIR.0000151805.86933.35 Almutairi, 2009, Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia, Liver Transpl, 15, 504, 10.1002/lt.21710 Barnard, 2016, Medical management of metabolic complications of liver transplant recipients, Gastroenterol Hepatol (N Y), 12, 601 Lee, 2007, Omega-3 fatty acids and liver disease, Hepatology, 45, 841, 10.1002/hep.21645 Targher, 2016, Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis, J Hepatol, 65, 589, 10.1016/j.jhep.2016.05.013 Hung, 2015, Nonalcoholic fatty liver disease is associated with QT prolongation in the general population, J Am Heart Assoc, 4, e001820, 10.1161/JAHA.115.001820 Mantovani, 2016, Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring, Diabetes Care, 39, 1416, 10.2337/dc16-0091 Targher, 2014, Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes, Nutr Metab Cardiovasc Dis, 24, 663, 10.1016/j.numecd.2014.01.005 Pereira, 2013, Patients with a high risk for obstructive sleep apnea syndrome: postoperative respiratory complications, Rev Port Pneumol, 19, 144, 10.1016/j.rppneu.2013.01.003 Sanchez-Torrijos, 2017, Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: what we do, what we should do, World J Hepatol, 9, 697, 10.4254/wjh.v9.i15.697 2016, EASL clinical practice guidelines: liver transplantation, J Hepatol, 64, 433, 10.1016/j.jhep.2015.10.006 Ripoll, 2011, The heart in liver transplantation, J Hepatol, 54, 810, 10.1016/j.jhep.2010.11.003 Tsochatzis, 2019, International liver transplantation consensus statement on end-stage liver disease due to nonalcoholic steatohepatitis and liver transplantation, Transplantation, 103, 45, 10.1097/TP.0000000000002433 Patel, 2018, Coronary artery disease in decompensated patients undergoing liver transplantation evaluation, Liver Transpl, 24, 333, 10.1002/lt.25012 Romero-Cristobal, 2019, Clinical utility of a risk-adapted protocol for the evaluation of coronary artery disease in liver transplant recipients, Liver Transpl, 25, 1177, 10.1002/lt.25493 Patel, 2019, The impact of coronary artery disease and statins on survival after liver transplantation, Liver Transpl, 25, 1514, 10.1002/lt.25613 Di Maira, 2015, Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients, Liver Transpl, 21, 812, 10.1002/lt.24128 VanWagner, 2017, A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score, Hepatology, 66, 1968, 10.1002/hep.29329 Izzy, 2020, Redefining cirrhotic cardiomyopathy for the modern era, Hepatology, 71, 334, 10.1002/hep.30875 Kong, 2015, Preoperative coronary calcium score is predictive of early postoperative cardiovascular complications in liver transplant recipients, Br J Anaesth, 114, 437, 10.1093/bja/aeu384 Vanwagner, 2012, Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events, Hepatology, 56, 1741, 10.1002/hep.25855 Rachwan, 2020, Postoperative atrial fibrillation and flutter in liver transplantation: an important predictor of early and late morbidity and mortality, Liver Transpl, 26, 34, 10.1002/lt.25631 Yasui, 2011, Nonalcoholic steatohepatitis and increased risk of chronic kidney disease, Metabolism, 60, 735, 10.1016/j.metabol.2010.07.022 Musso, 2014, Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis, PLoS Med, 11, e1001680, 10.1371/journal.pmed.1001680 Fussner, 2014, The impact of gender and NASH on chronic kidney disease before and after liver transplantation, Liver Int, 34, 1259, 10.1111/liv.12381 Singal, 2016, Nonalcoholic steatohepatitis is the most rapidly growing indication for simultaneous liver kidney transplantation in the United States, Transplantation, 100, 607, 10.1097/TP.0000000000000945 Bunnapradist, 2007, Evaluation of adult kidney transplant candidates, Am J Kidney Dis, 50, 890, 10.1053/j.ajkd.2007.08.010 Allen, 2019, The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study, J Hepatol, 71, 1229, 10.1016/j.jhep.2019.08.018 Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005 Lunati, 2013, Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors, Dig Liver Dis, 45, 833, 10.1016/j.dld.2013.03.009 Della Corte, 2017, Good adherence to the mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: the results of an Italian study, Nutrition, 39-40, 8, 10.1016/j.nut.2017.02.008 Buettner, 2013, Olive oil attenuates the cholesterol-induced development of nonalcoholic steatohepatitis despite increased insulin resistance in a rodent model, Horm Metab Res, 45, 795, 10.1055/s-0033-1353209 Suarez, 2017, Mediterranean diet and multi-ingredient-based interventions for the management of non-alcoholic fatty liver disease, Nutrients, 9, 1052, 10.3390/nu9101052 Molloy, 2012, Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis, Hepatology, 55, 429, 10.1002/hep.24731 Epstein, 2004, Aerobic capacity is associated with 100-day outcome after hepatic transplantation, Liver Transpl, 10, 418, 10.1002/lt.20088 Berzigotti, 2017, Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study, Hepatology, 65, 1293, 10.1002/hep.28992 Debette-Gratien, 2015, Personalized adapted physical activity before liver transplantation: acceptability and results, Transplantation, 99, 145, 10.1097/TP.0000000000000245 Brustia, 2018, Physical exercise in cirrhotic patients: towards prehabilitation on waiting list for liver transplantation. A systematic review and meta-analysis, Clin Res Hepatol Gastroenterol, 42, 205, 10.1016/j.clinre.2017.09.005 Berzigotti, 2016, Physical activity and liver diseases, Hepatology, 63, 1026, 10.1002/hep.28132 2019, EASL Clinical Practice Guidelines on nutrition in chronic liver disease, J Hepatol, 70, 172, 10.1016/j.jhep.2018.06.024 Krasnoff, 2006, A randomized trial of exercise and dietary counseling after liver transplantation, Am J Transplant, 6, 1896, 10.1111/j.1600-6143.2006.01391.x Garcia, 2014, Effect of a physical exercise program on the functional capacity of liver transplant patients, Transplant Proc, 46, 1807, 10.1016/j.transproceed.2014.05.023 Moya-Najera, 2017, Combined resistance and endurance training at a moderate-to-high intensity improves physical condition and quality of life in liver transplant patients, Liver Transpl, 23, 1273, 10.1002/lt.24827 Dunn, 2020, Physical function, physical activity, and quality of life after liver transplantation, Liver Transpl, 26, 702, 10.1002/lt.25742 Rongies, 2011, Physical activity long-term after liver transplantation yields better quality of life, Ann Transplant, 16, 126, 10.12659/AOT.882005 Painter, 2001, Physical activity and health-related quality of life in liver transplant recipients, Liver Transpl, 7, 213, 10.1053/jlts.2001.22184 Vilar-Gomez, 2020, Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis, Hepatology, 71, 495, 10.1002/hep.30368 Abner, 2011, Vitamin E and all-cause mortality: a meta-analysis, Curr Aging Sci, 4, 158, 10.2174/1874609811104020158 Ballon-Landa, 2018, Nutrition, physical activity, and lifestyle factors in prostate cancer prevention, Curr Opin Urol, 28, 55, 10.1097/MOU.0000000000000460 Schurks, 2010, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, BMJ, 341, c5702, 10.1136/bmj.c5702 Klein, 2011, Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT), JAMA, 306, 1549, 10.1001/jama.2011.1437 Garcia-Tsao, 2020, Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension, J Hepatol, 72, 885, 10.1016/j.jhep.2019.12.010 Younossi, 2019, Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 394, 2184, 10.1016/S0140-6736(19)33041-7 Germani, 2019, Management of recurrent and de novo NAFLD/NASH after liver transplantation, Transplantation, 103, 57, 10.1097/TP.0000000000002485 Haddad, 2006, Cyclosporin versus tacrolimus for liver transplanted patients, Cochrane Database Syst Rev, CD005161 Saliba, 2013, Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study, Am J Transplant, 13, 1734, 10.1111/ajt.12280 Charlton, 2017, Everolimus is associated with less weight gain than tacrolimus 2 Years after liver transplantation: results of a randomized multicenter study, Transplantation, 101, 2873, 10.1097/TP.0000000000001913 Hernandez, 2003, Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus, Transplant Proc, 35, 1727, 10.1016/S0041-1345(03)00630-4 Trotter, 2001, Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus, Liver Transpl, 7, 401, 10.1053/jlts.2001.23916 De Simone, 2017, Use of everolimus in liver transplantation: recommendations from a working group, Transplantation, 101, 239, 10.1097/TP.0000000000001438